Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This study is a single arm, multi-centre phase II study of olaparib and bevacizumab
combination therapy in subjects with relapsed small cell lung cancer (SCLC) as a second or
third line (systemic) therapy.
Subjects will receive olaparib and bevacizumab combination therapy. The arm is composed of 28
subjects.
Olaparib 300 mg bid per os every 12 hours administered each cycle day and bevacizumab 15
mg/kg via IV administered on Day 1 of every cycle for every 3 weeks. One cycle consists of 21
days.